Objectives: 1) To assess whether exercise training attenuates the adverse effects of treatment 5 in newly diagnosed prostate cancer patients beginning androgen deprivation therapy (ADT), 6 and 2) to examine whether exercise-induced improvements are sustained after the withdrawal 7 of supervised exercise. 8 Patients and methods: Fifty prostate cancer patients scheduled for ADT were randomised to 9 an exercise group (n = 24) or a control group (n = 26). The exercise group completed 3-months 10 of supervised aerobic and resistance exercise training (2x/week for 60 min), followed by 3-11 months of self-directed exercise. Outcomes were assessed at baseline, 3-months, and 6-months. 12 The primary outcome was difference in fat mass at 3-months. Secondary outcomes included 13 fat-free mass, cardiopulmonary exercise testing variables, QRISK2 score, anthropometry, 14 blood-borne biomarkers, fatigue, and quality of life (QoL).
Introduction 27
Androgen deprivation therapy (ADT) is often the first-line treatment for locally advanced and 28 metastatic prostate cancer. Whilst the therapeutic benefits of ADT are well-established [1] , it 29 is associated with several adverse side-effects, including increased body fat and reduced 30 skeletal muscle mass [2] . ADT also leads to reduced cardiopulmonary fitness and functional 31 capacity [3, 4] , as well as increased fatigue and incidence of metabolic syndrome [5, 6] . These 32 negative changes can the increase risk of a cardiovascular event and reduce health-related 33 quality of life (QoL) [7, 8] . 34 Exercise has been recognised as a potential strategy for managing the adverse effects of ADT 35 [9] . A recent meta-analysis of 15 studies showed that exercise training can improve aerobic 36 capacity and mitigate ADT-related increases in body fat in prostate cancer patients [10] . 37 However, with scant exception [11] , this evidence relates to the effects of exercise in patients 38 that have already developed adverse effects from receiving long-term ADT. Given that these 39 adverse health effects occur rapidly in the early stages of treatment [12, 13] , it is pertinent to 40 explore whether exercise administered concurrently with the initiation of ADT could retard or 41 prevent treatment toxicities. 42 To date, only one study has prescribed exercise at the commencement of ADT. Cormie et al. 43 [11] reported beneficial effects of a 3-month supervised exercise intervention on body 44 composition, strength, blood lipid profile, cardiopulmonary fitness and QoL in 63 prostate 45 cancer patients beginning ADT at a single-centre [11] . However, it is unknown whether 46 exercise-induced improvements can be maintained over the longer-term after withdrawal of 47 supervised exercise. This is important because treatment-associated side-effects continue to 48 develop after the first 3-months of ADT [3, 14] and reductions in strength and physical function 49 have been observed just 3-months after the cessation of supervised exercise in older adults [15] . The primary outcome was difference in body fat mass at 3-months. This was chosen because 150 adiposity has shown a high propensity to increase during the initial phases of ADT, more so 151 than other measures [25] , which highlights the importance of targeting body fat at this stage of 152 treatment. To our knowledge, Cormie et al. [11] is the only previous study to have investigated 153 the effects of exercise in prostate cancer patients initiating ADT, reporting an adjusted mean 154 difference in body fat mass of 1.4 kg (p = 0.001) at 3-months. An SD of 1.6 kg was obtained 155 from the adjusted mean difference and p-value using Cochrane guidelines [26] . Therefore, 44 156 participants (22 per group) were required to detect a between-group difference of 1.4 kg 157 assuming SD = 1.6 kg, numerator df = 1,  = 0.05 and 1-β = 0.8, which was calculated using 158 G*Power version 3.1. An attrition rate of 20% was also factored into the sample size 159 calculation.
160

Statistical analysis 161
Analyses were performed by intention to treat using R (R Foundation for Statistical Computing,
162
Vienna, Austria). Between-group differences in outcomes at 3-months and 6-months were 163 assessed by analysis of covariance (ANCOVA), with baseline values as covariates. The 164 adjusted mean differences with 95% confidence intervals are presented. Statistical significance 165 was set at a two-tailed p < 0.05. To comply with intention to treat and increase precision of the 166 estimates, missing data at 3-months (n = 8) and 6-months (n = 13) were multiply imputed using 167 predictive mean matching with 20 iterations. At the end of the 20 iterations, one imputed data 168 set was created and the process was repeated to generate 20 imputed data sets. ANCOVA 169 9 models were fitted on each imputed data set, and the results from each model were then pooled 170 into a single set of estimates and standard errors using Rubin's rules [27] . For participants who 171 had missing data at 3-months, baseline values and other covariates were entered into the 172 imputation model. When data were missing at 6-months, baseline and 3-month endpoint values 173 with covariates were used to impute missing values. Outcomes with missing data at baseline 174 were not included in the analysis. Data and analyses scripts can be accessed online [28] .
175
Results
176
Recruitment, retention and adherence to the intervention 177 Of the 186 prostate cancer patients screened for eligibility, 39 were excluded due to bone 178 metastasis or medical conditions limiting exercise. A further 97 patients declined to participate 179 citing various reasons such as work commitments and fearing that treatment might be delayed 180 because they had to complete baseline testing before receiving the ADT injection. Hence, 50 181 patients enrolled on the study and were randomised (Figure 1) . At 3-months, two patients in 182 the exercise group and two in the control group withdrew from the study due to a lack of 183 motivation/interest. Four patients in the control group also missed the 3-month assessment time 184 point due to conflicting schedules. A total of 13 patients missed the assessment at 6-months.
185
All patients in the exercise group completed at least 17 out of a possible 24 supervised sessions 186 (≥ 70%). There were no adverse events reported during training or testing. antianginal/antihypertensive drugs (58%) and statins (52%). The incidence of metastasis at 195 baseline was 42% and the majority of participants had a Gleason score of 7-8 (52%). The 196 average risk of having a cardiovascular event in the next 10 years was 26.8%. Outcomes at 197 each time point are presented in Table 2 . 198 Outcomes at 3-months 199 Exercise prevented the decline in cardiopulmonary fitness, with significant between-group 200 differences found in V O2peak, VT, and OUES (Table 3) . Exercise also prevented the increase in 201 fatigue observed in the control group, as indicated by a significantly higher FACIT-Fatigue 202 score. As expected, serum testosterone concentrations declined in both groups (indicative of 203 severe hypogonadism), which was accompanied by reductions in PSA (Table 2 ). There was no 204 evidence for differences in blood-borne biomarkers, body composition, cardiovascular disease 205 risk, or hand grip strength (Table 3) .
206
Outcomes at 6-months 207 After the withdrawal of supervision, the exercise group maintained self-directed levels of 208 exercise, as evidenced by the between-group difference in GodinQ (Table 3) . Despite this, the 209 significant between-group differences in cardiorespiratory and fatigue observed at 3-months 210 were not maintained (Table 3) . However, the exercise group reported higher QoL at 6-months 211 compared to controls. Exercise also prevented adverse changes in QRISK2 score (Table 3) , 212 indicating a reduced cardiovascular event risk compared to the control group. There was no 213 evidence for differences in blood-borne biomarkers, body composition, or hand grip strength 214 (Table 3) . This is the first study to assess whether the effects of supervised exercise in prostate cancer 217 patients beginning ADT can be maintained after the withdrawal of supervision. The 3-month 218 aerobic and resistance training intervention prevented adverse changes in cardiorespiratory 219 fitness and fatigue. After the supervised exercise was withdrawn, differences in 220 cardiorespiratory fitness and fatigue were not sustained, but the exercise group showed higher 221 QoL and a reduced cardiovascular event risk compared to the control group. These findings 222 have important implications for clinicians concerned with the management of ADT-related 223 side-effects.
224
Our data showed no evidence for an effect of exercise on fat mass in men commencing ADT, 225 which was our primary outcome. Although the adjusted mean difference favoured the exercise 226 group at 3-months (-1.9. kg), the 95% confidence intervals showed that true mean difference 227 is likely to lie somewhere between -4.9 to 0.9 kg, indicating a high level of uncertainty. The at 3-months. The adjusted mean difference in V O2peak (1.9 ml.kg -1 .min -1 ) was of a similar 242 magnitude to that reported previously in prostate cancer patients after 3-months of aerobic and 243 resistance training at the commencement of ADT (1.1 ml.kg -1 .min -1 ) [11] . Although the 244 minimal clinically important difference (MCID) in V O2peak for prostate cancer patients is 245 currently unknown, an increase of 1.8 ml.kg -1 .min -1 following 6-months of exercise training 246 has been associated with improved PSA doubling time (R 2 = 0.41, p < 0.003) [35] . This finding 247 suggests a link between improved cardiopulmonary exercise capacity and prostate cancer 248 progression, which is consistent with the reported inverse relationship between vigorous 249 physical activity and biochemical recurrence in newly diagnosed prostate cancer patients [36] .
250
Other evidence also suggests that cardiopulmonary fitness is associated with reduced relative 251 risk of cancer mortality and chronic disease [37, 38] .
252
In addition to maintaining V O2peak, this study is the first to demonstrate that supervised exercise 253 prevents the reduction in VT in patients receiving ADT. This is an important finding because 254 VT predicts clinical outcomes in the oncological setting independent of V O2peak [39] . 255 Moreover, the VT is not influenced by patient volition [22] , and therefore the improvement 256 occurred independent of motivational factors during the CPET. Furthermore, VT is limited by 257 the rate of oxygen utilisation at the muscle as opposed to V O2peak, which is primarily limited 258 by delivery of oxygen to the muscle [40] , although this could be influenced by age-related 259 diseases such as sarcopenia. As such, VT represents a unique peripheral muscle adaptation in 260 response to exercise training.
261
The exercise group reported less fatigue than controls at 3-months. The between-group 262 difference in FACIT-Fatigue score (4.5 points) is clinically relevant given that the MCID has 
280
Despite this, maintaining self-directed exercise after the supervised exercise was withdrawn 281 attenuated the adverse effects that ADT had on QoL. Specifically, the adjusted mean difference 282 (8.5 points) in FACT-P at 6-months favoured the exercise group; a difference that is clinical 283 meaningful [45] . A meta-analysis of three studies previously showed that exercise has a 284 moderately beneficial effect (standardised mean difference = 0.36) on disease-specific QoL in 285 prostate cancer patients undergoing ADT [46] . Secondary to increasing patient longevity, 286 maintaining patient QoL is a key objective for physicians prescribing treatment for diseases 287 such as prostate cancer [47] . Indeed, there have been calls for clinicians to provide supportive 288 care alongside standard therapy to optimise the management of advanced prostate cancer [48] .
289
The findings of this RCT suggest that a short-term programme of supervised exercise training 290 14 commenced at the beginning of ADT is an effective, non-pharmacological strategy for 291 preventing treatment-related reductions in QoL.
292
Regular exercise also prevented the adverse effect of ADT on cardiovascular events risk, as 293 evidence by the significant difference in QRISK2 score at 6-months (-2.9%, p = 0.041). This 
304
There were some limitations to this study. The intervention involved a 3-month programme of 305 supervised exercise led by exercise specialists, which may not be deliverable within healthcare 306 systems. In addition, the trial was only powered to detect differences in fat mass and may not 307 have been adequately powered to detect differences in some of the secondary outcomes.
308
Furthermore, using self-report questionnaires to assess physical activity can be prone to 309 subjective bias, although anecdotal evidence from the patients helped confirm that the exercise 310 group maintained self-directed exercise after the supervised exercise intervention was 311 withdrawn.
312
In conclusion, 3-months of supervised aerobic and resistance training followed by 3-months of 313 self-directed exercise provided a sustained benefit to QoL and cardiovascular event risk in 
Strength
Hand grip (kg) 0.46 (-1.5, 2.5) 0.65 1.0 (-0.67, 2.7) 0.23
CV event risk
QRISK2 (%) -0.46 (-2.8, 1.9) 0.68 -2.9 (-5.8, 0.13) 0.041 95% CI = confidence interval; CPET = cardiopulmonary exercise test; CV = cardiovascular;
FACIT-Fatigue = Functional Assessment of Chronic Illness Therapy-Fatigue; FACT-P = Functional Assessment of Cancer Therapy-Prostate; FFMfat-free mass; GodinQ = Godin Leisure-Time Exercise Questionnaire; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; OUES = oxygen uptake efficiency slope; p = p-value; PROs = patient reported outcomes; PSA = prostate specific antigen; SHGB = sex hormone binding globulin; VT = ventilatory threshold; VCO2 = carbon dioxide output; V E = minute ventilation; VO2 = oxygen uptake; V O2peak = peak oxygen uptake. Completed assessment (n =20)
3-months
Randomised (n = 50)
Completed assessment (n = 18) Completed assessment (n =19)
Analysed by intention to treat (n = 24)  Missing baseline data for grip strength (n = 1), PSA (n = 1), fat mass (n = 1), SHBG (n = 2), insulin (n = 2), and FFM (n = 1).
Analysed by intention to treat (n = 26)  Missing baseline data for testosterone (n = 1), VT (n = 1), grip strength (n = 2), fat mass (n = 2), SHGB (n = 2), insulin (n = 1), FFM = (n = 2), and FACT-P (n = 1).
Allocation
6-months
Analysis
